Trial Profile

A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obrixtamig (Primary) ; Ezabenlimab
Indications Large cell carcinoma; Neuroendocrine carcinoma; Small cell lung cancer
Focus Adverse reactions
Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International

04 Aug 2026 Planned End Date changed from 30 Jun 2026 to 31 Mar 2027.
28 Apr 2026 Actual primary completion date changed from 11 Jun 2025 to 31 Dec 2026.
24 Oct 2025 Phase amended from I/II to I.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com